Rare NRG1 Fusion Market report has been added to Delveinsight. It is one of the best comprehensive and important additions to the market research report.
Rare NRG1 Fusion Disease Overview
NRG1 gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Solid Tumors are heterotypic aggregates of many cell types, including cancer cells, cancer stem cells, connective-tissue cells, and immune cells. Solid Tumors can develop in the muscles, bone, and organs of the body. Tumor cells have both inherited and somatic variants in their genome. Alterations in oncogenes, tumor-suppressor genes, and micro-RNA genes are important in the pathogenesis of cancer.
Get Free Sample Copy- https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market
Rare NRG1 Fusion Key Players
Rare NRG1 Fusion Drugs
Rare NRG1 Fusion Market Report
NRG1-fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Genetic sequencing allows the identification of the gene fusion.
Rare NRG1 Fusion Market Insights
For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents.
Rare NRG1 Fusion Treatment Market
NRG1 gene fusions result in activation of ErbB2-/ErbB3-mediated signaling pathways and may function as oncogenic drivers. NRG1 fusions have emerged as a potential therapeutic target across multiple tumor types, including NSCLC. For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents.
Rare NRG1 Fusion Market Research Report
The fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1 fusions are present at a low incidence in multiple tumor types but are enriched in invasive mucinous adenocarcinomas (IMAs) of the lung. NRG1 is an abbreviation for neuregulin-1, sometimes also called heregulin.
Rare NRG1 Fusion Market Report Scope
Table of content
1. Key Insights
2. Report Introduction
3. Rare NRG1 Fusion Market Overview at a Glance
4. Executive Summary of Rare NRG1 Fusion
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. The United States
9. EU-5
10. Japan
11. China
12. Patient Journey
13. Key Endpoints in NRG1 Fusion Clinical Trials
14. Emerging Therapies
15. Rare NRG1 Fusion: 8 Major Market Analysis
16. The United States Market Size
17. EU-5 Market Size
18. Japan
19. China
20. Market Drivers
21. Market Barriers
22. SWOT Analysis
23. Unmet Needs
24. Appendix
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
Why should you buy this report?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/